Human Muscle Gene Expression Profiles in Young and Old Men (CERA)

This study has been completed.
Sponsor:
Collaborators:
Fondation des Caisses d'Epargne Rhône-Alpes
Institut National de la Recherche Agronomique
Information provided by:
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT00725166
First received: July 29, 2008
Last updated: June 9, 2009
Last verified: June 2009

July 29, 2008
June 9, 2009
October 2008
March 2009   (final data collection date for primary outcome measure)
To identify the differential expression profiles (proteomics, transcriptomics) in skeletal muscle between young and old men [ Time Frame: During biopsie (W3) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00725166 on ClinicalTrials.gov Archive Site
  • To specify the localisation of the major biomarkers in the muscle biopsies. [ Time Frame: During biopsie (W3) ] [ Designated as safety issue: No ]
  • To compare muscular energy metabolic enzymatic activities between young and old men [ Time Frame: during biopsie (W3) ] [ Designated as safety issue: No ]
  • To compare the number of muscular stem cells between young and old men [ Time Frame: during biopsie (W3) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Human Muscle Gene Expression Profiles in Young and Old Men
Human Muscle Gene Expression Profiles in Young and Old Men

To reach the goals of living longer in better medical conditions, many countries reach the same conclusion: new strategies have to be developed to avoid, or at least limit, the effects of age; this requires a better knowledge of the mechanisms of aging. Our project focuses on the loss of muscle mass associated with aging, called sarcopenia. Sarcopenia unavoidably leads to impaired mobility and poor balance, which contributes to loss of functional autonomy and to increased prevalence for severe falls. Skeletal muscle also plays a central role as a reserve for energy and amino acids. Hence, sarcopenia further triggers severe side metabolic effects such as frailty among elderly persons. The precise mechanisms of muscle aging are still mostly unknown, although many theories have been proposed.

The present study aims at better understanding the mechanisms of skeletal muscle loss associated with aging. Using muscle biopsies from young and old subjects, the differential expression profiles of mRNA will be obtained through chips that will evaluate more than 39000 transcripts. On the same samples, proteomic analyses will involve two complementary approaches: (1) bidimensional electrophoresis (2DGE) coupled to mass spectrometry (MALDI-ToF) for dominant proteins; (2) Western-blot (more than 800 antibodies) targeting regulating proteins not detectable using 2DGE. Complementary histological studies (immunohisto-fluorescence, confocal microscopy) will specify the localisation of the major biomarkers in the muscle biopsies.

The results of that research will have applications in the medium term and will lead to nutritional interventions to modulate specific metabolic pathways and improve the quality of life in the elderly.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Serum, muscle

Non-Probability Sample

Young : students of the Saint-Etienne's university. Old : men who participate in the PROOF study

  • Elderly
  • Sarcopenia
Other: Skeletal muscle aging

W1 - Blood test

  • Maximal voluntary contraction of quadriceps
  • Hydrostatic weighing

W2 - Maximal metabolic test using a cycloergometer

W3 - Muscular biopsy

  • Young
    Young men 19-25 years old
    Intervention: Other: Skeletal muscle aging
  • Old
    old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
    Intervention: Other: Skeletal muscle aging
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
41
March 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Affiliated or beneficiary of a social security category
  • Having signed the inform consent form
  • Having signed the genetic consent form

Exclusion Criteria:

  • Antiaggregant platelet treatment
  • Type 2 diabetes
  • Body Mass Index > 25
  • Severe renal disease
  • CRP > 10
  • Abnormal clotting test
  • Allergies to local anesthetics
Male
19 Years to 76 Years
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00725166
0708102, 2008-A00374-51
No
Clément CAILLAUX, CHU de Saint-Etienne
Centre Hospitalier Universitaire de Saint Etienne
  • Fondation des Caisses d'Epargne Rhône-Alpes
  • Institut National de la Recherche Agronomique
Study Chair: Daniel BECHET, PhD INRA Clermont-Ferrand
Principal Investigator: Jean-Claude BARTHELEMY, MD PhD CHU de Saint-Etienne
Centre Hospitalier Universitaire de Saint Etienne
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP